Caedo Oncology
1 known investors
Caedo Oncology develops cancer immunotherapies, including CO-1, a bifunctional anti-CD47 monoclonal antibody that blocks SIRPα–CD47 interactions and induces programmed cell death of cancer cells. The company targets improved treatment options for cancer patients.
BiotechHealthtech
Investors · 1
Frequently asked questions
- What does Caedo Oncology do?
- Caedo Oncology develops cancer immunotherapies, including CO-1, a bifunctional anti-CD47 monoclonal antibody that blocks SIRPα–CD47 interactions and induces programmed cell death of cancer cells. The company targets improved treatment options for cancer patients.
- Who are Caedo Oncology's investors?
- Caedo Oncology's investors include Farvatn Venture.